JNCI: Quality of life of cancer patients treated with immune checkpoint inhibitors

Immunotherapy has aroused widespread scientific and clinical interest because it can prolong the survival time of cancer patients with poor prognosis

Immune immune checkpoint inhibitors (ICI, such as nivolumab, pembrolizumab, ipilimumab, etc.

This study is a meta-analysis designed to outline changes in QOL and symptoms in cancer patients treated with ICI

According to the PRISMA guidelines, researchers retrieved studies from multiple databases that reported QOL data of cancer patients who received ICI treatment published before November 2019

Differences in QOL changes between ICI and non-ICI treatment groups

Differences in QOL changes between ICI and non-ICI treatment groups

A total of 20,323 articles were screened , 26 of which met the inclusion criteria

Screening the overall QOL of cancer patients treated with ICI did not change over time The overall QOL of cancer patients treated with ICI did not change over time Compared with patients receiving non-ICI regimens , the overall QOL of patients receiving ICI treatment QOL has a greater degree of improvement Compared with patients receiving non-ICI regimens, the overall QOL of patients receiving ICI treatment has a greater degree of improvement

In terms of symptoms, loss of appetite, insomnia, and pain severity were reduced in patients receiving ICI treatment, but the severity of dyspnea increased (k=14, n=3243-3499, p<0.

In terms of symptoms, loss of appetite, insomnia, and pain severity in patients who received ICI treatment decreased, but the severity of dyspnea increased.

The overall quality of life reported by cancer patients who received ICI treatment did not change significantly, and it was better than those who received non-ICI treatment.

Original source:

Gonzalez Brian D,Eisel Sarah L,Bowles Kristina E et al.

Meta-Analysis of Quality of Life in Cancer Patients Treated with Immune Checkpoint Inhibitors

in this message